Literature DB >> 590309

The pharmacokinetics of cefuroxime after intravenous injection.

P E Gower, C H Dash.   

Abstract

Cefuroxime, a new cephalosporin antibiotic which is stable to most beta-lactamases produced by gram-negative bacteria, was given by bolus intravenous injection to six volunteers in doses of 500 mg and 750 mg. The concentrations of cefuroxime in serum and urine were measured at pre-determined times after injection and the data analysed by a two-compartment open system model. A serum concentration of 8 microgram/ml was exceeded for 100.3 min (+/- 18.3) after a 500 mg dose and for 144.5 min (+/- 19.8) after 750 mg. The ultimate serum half-life was 1.1 h. Excretion of cefuroxime in the urine was almost complete in 24 h, the clearance being 150 ml/min/1.73m2. About 45% was excreted through the renal tubules. The injections were well tolerated and no changes in haematological or biochemical values were seen. The resulting data are compared with those published for some other cephalosporins. It is concluded that the favourable pharmacokinetics, especially the high concentrations of unbound cefuroxime in the serum, are likely to aid effective therapy of human infection caused by sensitive bacteria.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 590309     DOI: 10.1007/bf00609865

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  15 in total

1.  Pharmacological studies with cefamandole in human volunteers.

Authors:  B R Meyers; B Ribner; S Yancovitz; S Z Hirschman
Journal:  Antimicrob Agents Chemother       Date:  1976-01       Impact factor: 5.191

2.  Cefuroxime: pharmacokinetics after a short infusion, and in vitro activity against hospital pathogens.

Authors:  C S Goodwin; C H Dash; J P Hill; A D Goldberg
Journal:  J Antimicrob Chemother       Date:  1977-05       Impact factor: 5.790

3.  Pharmacokinetics of cefazolin in normal and uremic subjects.

Authors:  P G Welling; W A Craig; A L Gordon; C M Kunin
Journal:  Clin Pharmacol Ther       Date:  1974-04       Impact factor: 6.875

4.  Pharmacokinetics of cefazolin compared with four other cephalosporins.

Authors:  W M Kirby; C Regamey
Journal:  J Infect Dis       Date:  1973-10       Impact factor: 5.226

5.  Pharmacokinetics of the cephalosporins in healthy volunteers and uremic patients.

Authors:  W M Kirby; J B De Maine; W S Serrill
Journal:  Postgrad Med J       Date:  1971-02       Impact factor: 2.401

6.  Cefuroxime - a new cephalosporin antibiotic.

Authors:  C H O'Callaghan; R B Sykes; D M Ryan; R D Foord; P W Muggleton
Journal:  J Antibiot (Tokyo)       Date:  1976-01       Impact factor: 2.649

7.  Effects of rate of infusion and probenecid on serum levels, renal excretion, and tolerance of intravenous doses of cefoxitin in humans: comparison with cephalothin.

Authors:  C S Goodwin; E B Raftery; A D Goldberg; H Skeggs; A E Till; C M Martin
Journal:  Antimicrob Agents Chemother       Date:  1974-09       Impact factor: 5.191

8.  Cefoxitin and cephalothin: antimicrobial activity, human pharmacokinetics, and toxicology.

Authors:  W Brumfitt; J Kosmidis; J M Hamilton-Miller; J N Gilchrist
Journal:  Antimicrob Agents Chemother       Date:  1974-09       Impact factor: 5.191

9.  Cefuroxime, a new cephalosporin antibiotic: activity in vitro.

Authors:  C H O'Callaghan; R B Sykes; A Griffiths; J E Thornton
Journal:  Antimicrob Agents Chemother       Date:  1976-03       Impact factor: 5.191

10.  Estimation of volume of distribution and half-life of a compound after rapid intravenous injection.

Authors:  J G Wagner; J I Northam
Journal:  J Pharm Sci       Date:  1967-04       Impact factor: 3.534

View more
  17 in total

1.  Assessment of cefazolin and cefuroxime tissue penetration by using a continuous intravenous infusion.

Authors:  J E Connors; J T DiPiro; R G Hayter; K D Hooker; J A Stanfield; T R Young
Journal:  Antimicrob Agents Chemother       Date:  1990-06       Impact factor: 5.191

2.  A population pharmacokinetic model for cefuroxime using cystatin C as a marker of renal function.

Authors:  Anders Viberg; Anders Lannergård; Anders Larsson; Otto Cars; Mats O Karlsson; Marie Sandström
Journal:  Br J Clin Pharmacol       Date:  2006-09       Impact factor: 4.335

Review 3.  Renal Drug Transporters and Drug Interactions.

Authors:  Anton Ivanyuk; Françoise Livio; Jérôme Biollaz; Thierry Buclin
Journal:  Clin Pharmacokinet       Date:  2017-08       Impact factor: 6.447

4.  The human pharmacokinetics of cefotaxime and its metabolites and the role of renal tubular secretion on their elimination.

Authors:  R M Ings; D S Reeves; L O White; R P Bax; M J Bywater; H A Holt
Journal:  J Pharmacokinet Biopharm       Date:  1985-04

5.  Cephalosporin activity.

Authors: 
Journal:  Br Med J       Date:  1978-07-22

6.  Cefamandole and beta-lactamases.

Authors:  S Selwyn
Journal:  Br Med J       Date:  1978-06-10

Review 7.  Cefuroxime: a review of its antibacterial activity, pharmacological properties and therapeutic use.

Authors:  R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1979-04       Impact factor: 9.546

Review 8.  Clinical pharmacokinetics of antibiotics in patients with impaired renal function.

Authors:  W L St Peter; K A Redic-Kill; C E Halstenson
Journal:  Clin Pharmacokinet       Date:  1992-03       Impact factor: 6.447

9.  Human pharmacology of cefotaxime (HR 756), a new cephalosporin.

Authors:  R Lüthy; R Münch; J Blaser; H Bhend; W Siegenthaler
Journal:  Antimicrob Agents Chemother       Date:  1979-08       Impact factor: 5.191

10.  Comparative pharmacokinetics of cefuroxime lysine after single intravenous, intraperitoneal, and intramuscular administration to rats.

Authors:  Long-shan Zhao; Ran Yin; Bin-bin Wei; Qing Li; Zhen-yuan Jiang; Xiao-hui Chen; Kai-shun Bi
Journal:  Acta Pharmacol Sin       Date:  2012-10-15       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.